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were seropositive. Because antibod-
ies may be detectable 10 days–3 
weeks after experimental infection 
for the first time (8), the presumed 
period of infection was between mid-
January and mid-February. At this 
time, the highest temperatures again 
rose above 6°C for a few days (Figure 
1, panel A).
Although the within-herd sero-
prevalence was >90% in ewes after 
confirmed or suspected SBV infection 
in 2011 (9), in this study, conducted 
during the cold season, only 12 (13%) 
of 90 tested sheep were positive by 
ELISA. Three animals seroconverted 
between mid-January and mid-Febru-
ary. Thus, SBV transmission appears 
to be possible at a low level, most like-
ly because of the low activity of the 
involved insect vectors.
In addition to the SBV cases 
found on the sheep holding in Meck-
lenburg–Western Pomerania, an ad-
ditional 52 confirmed SBV cases 
(defined as virus detection by qRT-
PCR or isolation in cell culture) in 
adult ruminants were reported to 
the German Animal Disease Report-
ing System from January 1 through 
February 20, 2013 (Figure, panel 
B). Most affected animal holdings 
were located in Bavaria, but cases 
were also reported from Thuringia, 
Saxony, Brandenburg, Mecklen-
burg–Western Pomerania, Hesse, and 
Lower Saxony. In conclusion, trans-
mission of SBV by hematophagous 
insects seems possible, even dur-
ing the winter in central Europe, if 
minimum temperatures rise above a 
certain threshold for several consecu-
tive days.
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Recurrent  
Bordetella holmesii 
Bacteremia and 
Nasal Carriage in a 
Patient Receiving 
Rituximab
To the Editor: We report a case 
of recurrent Bordetella holmesii bac-
teremia with 4 clinical manifestations: 
3 episodes of cellulitis and 1 episode 
of pneumonia. The patient, a 67-year-
old man, was admitted to the Pitié-
Salpêtrière hospital in Paris, France, in 
December 2010, for recurrent cellulitis 
in his left leg. Eleven years earlier, dif-
fuse large B-cell lymphoma had been 
diagnosed, and he had undergone 7 
chemotherapy courses. He also had 
received 2 autologous stem cell trans-
plants. He was receiving maintenance 
treatment with intravenous (IV) ritux-
imab every 3 months and IV immuno-
globulin for hypogammaglobulinemia.
The first episode of cellulitis had 
occurred in his left leg 2 months be-
fore admission; the condition was 
treated with pristinamycin (3 g/day 
for 14 days), and the leg healed com-
pletely. Cellulitis recurred in his left 
leg 2 months later; it was again treated 
with pristinamycin (3 g/day) for 4 
days in conjunction with fusidic acid. 
The cutaneous lesions worsened, and 
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he was admitted to the hospital with 
fever (38.6°C) and chills.
Clinical examination showed 
extended cellulitis; the left leg was 
bright red, hot, shiny, swollen, and 
non-pitting. The patient’s leukocyte 
count was 23 × 109/L (reference <10 
× 109/L) and C-reactive protein level 
was 332 mg/L (reference <5 mg/L). 
IV clindamycin and ceftriaxone were 
administered. Fever and other symp-
toms improved rapidly. Two consecu-
tive blood cultures carried out before 
antimicrobial drug treatment were 
positive for B. holmesii, according 
to biochemical characteristics and 
molecular detection of the specific 
B. holmesii recA gene (1). Isolates 
in both cultures were susceptible to 
amoxicillin, macrolide antimicrobial 
drugs, cefoxitin, nalidixic acid, and 
ciprofloxacin and were resistant to 
cefotaxime and trimethoprim/sulfa-
methoxazole (Table; blood isolate, day 
1). The antimicrobial drug regimen 
was changed to amoxicillin (6 g/day) 
for 14 days; the cellulitis resolved, and 
the patient was discharged.
Cellulitis in the right leg was di-
agnosed 2 weeks after the end of the 
previous treatment. Pristinamycin (3 
g/day) was prescribed by the man’s 
physician but was ineffective. He was 
readmitted, and B. holmesii was again 
isolated in 2 new blood cultures; the 
organism was now resistant to cefoxi-
tin (Table; blood isolate, day 24). Oral 
amoxicillin was initiated (6 g/day), 
without success, and after 1 week, IV 
ceftriaxone (2 g/day) was adminis-
tered. B. holmesii was again isolated 
(isolate blood, day 33) from blood 
cultures despite amoxicillin treatment, 
and the antibiogram had the same re-
sistance profile, except for amoxicillin 
(which was not determined). Because 
the patient was improving, IV ceftri-
axone was maintained for 18 days, 
and he was discharged 5 days after the 
beginning of efficient antimicrobial 
drug therapy.
Two weeks after the end of the 
treatment, the patient was admit-
ted to the hospital for bilateral pneu-
monia. Treatment with piperacillin/
tazobactam and ciprofloxacin for 14 
days (750 mg 2×/day) was initiated. 
B. holmesii was again isolated from 
blood; the bacterium had now ac-
quired resistance to amoxicillin and 
nalidixic acid (Table; isolate blood, 
day 74). Nevertheless, ciprofloxacin 
treatment was continued. By real-time 
PCR targeting of IS481, Bordetella 
DNA was detected in nasopharyngeal 
swab (NPS) specimens (1), but the 
species could not be identified because 
of an insufficient amount of DNA. 
One month after the end of the treat-
ment, the patient was recovering. Al-
though the patient was asymptomatic, 
B. holmesii was isolated in a second 
NPS specimen. The isolate was sensi-
tive to amoxicillin and macrolides and 
resistant to cefotaxime, nalidixic acid, 
trimethoprim, and trimethoprim/sulfa-
methoxazole (Table; isolate NPS, day 
105). Rituximab was discontinued, 
and relapse had not occurred after >1 
year of follow-up.
B. holmesii was first described 
in 1995 (2); it was primarily isolated 
from the blood of immunocompro-
mised patients, especially those with 
spleen dysfunction. Since 1999, B. 
holmesii has been detected during per-
tussis outbreaks in NPS specimens of 
patients with pertussis-like signs and 
symptoms (3–6). To our knowledge, 
the association between B. holmesii 
infection and rituximab treatment has 
been reported only once, in a renal 
transplant recipient, and B. holmesii 
nasal carriage was not tested for (7).
In this patient, the B. holmesii in-
fection relapses definitively stopped 
after rituximab treatment was inter-
rupted, which suggests a relation-
ship between the 2 events and that 
patients receiving rituximab are at 
increased risk for severe infection 
(8). Interpretations of antimicrobial 
drug resistance are difficult because 
no breakpoints have been defined for 
this species, but MICs of the drugs 
showed changes in the resistance 
profile between infectious episodes 
(Table). These observations strongly 
suggest a heterogeneous population 
of bacteria and that resistance was ac-
quired after antimicrobial drug treat-
ment as described in the United King-
dom (9). The patient improved while 
receiving ceftriaxone, although, in vi-
tro; the bacterium was found resistant 
to this antimicrobial drug family as 
reported (10). Thus, the in vitro sus-
ceptibility testing and in vivo efficacy 
were discordant.
In conclusion, the patient’s nasal 
carriage and rituximab treatment may 
explain the recurrent infection. That 
the nasal carriage was the primary 
mode of transmission could not be 
proven because NPS specimens were 
not taken early enough. More studies 
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Table.	Antimicrobial	resistance	profile	of	Bordetella holmesii isolates	in	vitro,	France,,	December	2010–March	2011* 
Antimicrobial	agent 
Antimicrobial	drug	MICs†, g/mL,	by	isolate‡ 
Blood,	d	1 Blood,	d	24 Blood,	d	33 Blood,	d	74 NPS,	d	105 
Amoxicillin <2 <2 NA# 16 <2 
Cefoxitin <8 >256 >256 >256 >256 
Cefotaxime >32 >32 >32 >32 >32 
Nalidixic	acid <16 <16 <16 64 >256 
Trimethroprim >32 >32 >32 >32 >32 
Sulfamethoxazole >512 >512 >512 >512 >512 
*MICs corresponding	to	a	drug	resistance,	which	may	reflect	the	general	interpretation	for	nonfermenting	bacteria,	are	in	boldface. NPS,	nasopharyngeal	
swab;	NA,	no	available	data. 
†MICs	were	determined	by	E-test	on	Bordet–Gengou	agar. 
‡Site	and	day	(d)	of	collection	of	isolate. 
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are needed to determine the role of 
nasal carriage in B. holmesii bacte-
remia. That no B. holmesii infections 
occurred after rituximab was stopped 
suggests that rituximab played a role 
in the recurrent infections. In cases of 
recurrent infection or bacteremia, na-
sal carriage should be assessed, and 
the interruption of rituximab should 
be considered by physicians.
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Rickettsia africae 
in Amblyomma 
variegatum Ticks, 
Uganda and Nigeria
To the Editor: Rickettsia africae 
is the most widespread spotted fever 
group (SFG) rickettsia in sub-Saharan 
Africa, where it causes African tick-
bite fever (1), an acute, influenza-like 
syndrome. The number of cases in 
tourists returning from safari in sub-
Saharan Africa is increasing (1). In 
western, central, and eastern sub-Sa-
haran Africa, R. africae is carried by 
Amblyomma variegatum (Fabricius, 
1794) ticks (2); usually associated 
with cattle, this 3-host tick also can 
feed on a variety of hosts, including 
humans (2). R. africae has not been re-
ported in Uganda and rarely reported 
in Nigeria (3,4). Our objective was to 
determine the potential risk for human 
infection by screening for rickettsial 
DNA in A. variegatum ticks from cat-
tle in Uganda and Nigeria.
In February 2010, ticks were col-
lected from zebu cattle (Bos indicus) 
from 8 villages in the districts of Ka-
beramaido (Adektar [1°81′N–33°22′ 
E], Awimon [1°66′N–33°04′ E], Kalo-
bo [1°88′ N–33°25′ E], Odidip [1°90′ 
N–33°30′ E], Odikara [1°91′ N–33°30′ 
E], and Olilimo [1°75′ N–33°38′ E], 
and Dokolo (Alela [2°09′ N–33°16′ 
E], and Angeta [1°87′ N–33°10′ E]) 
in Uganda and, in June 2010, in 3 
villages (Mangar [9°14′ N–8°93′ E], 
Ruff [9°43′ N–9°10′ E], and Tambes 
[9°38′ N–9°38′ E]) in the Plateau 
State in Nigeria (Figure). This con-
venience sample was obtained as part 
of other ongoing research projects in 
both countries. Ticks were preserved 
in 70% ethanol and identified mor-
phologically to the species level by 
using taxonomic keys (5). Because the 
anatomic features do not enable an ob-
jective assessment of the feeding sta-
tus of adult male ticks, engorgement 
level was determined only in female 
tick specimens and nymphs.
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